Biogen pulls controversial Alzheimer's drug Aduhelm
Biogen said it was discontinuing Aduhelm to put more resources into Leqembi, a newer Alzheimer's medicine that was fully approved in 2023 under the traditional regulatory pathway.A controversial A
Updated on: March 24,2024
14
Biogen pulls controversial Alzheimer's drug Aduhelm
Biogen said it was discontinuing Aduhelm to put more resources into Leqembi, a newer Alzheimer's medicine that was fully approved in 2023 under the traditional regulatory pathway.A controversial A
Updated on:March 24,2024
14